Shampa Das
About
Shampa Das is a scholar working on Pharmacology, Epidemiology and Molecular Medicine.
According to data from OpenAlex, Shampa Das has authored 49 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pharmacology, 26 papers in Epidemiology and 26 papers in Molecular Medicine. Recurrent topics in Shampa Das's work include Antibiotics Pharmacokinetics and Efficacy (34 papers), Antibiotic Resistance in Bacteria (26 papers) and Pneumonia and Respiratory Infections (20 papers). Shampa Das is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (34 papers), Antibiotic Resistance in Bacteria (26 papers) and Pneumonia and Respiratory Infections (20 papers). Shampa Das collaborates with scholars based in United Kingdom, United States and India. Shampa Das's co-authors include Devendra P. Dubey, Stuart H. Orkin, Roderick T. Bronson, Richard A. Van Etten, Carola A. Neumann, Daniela S. Krause, Christopher V. Carman, Yuko Fujiwara, Timi Edeki and Todd Riccobene and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Antimicrobial Agents and Chemotherapy.
In The Last Decade
Shampa Das
47 papers receiving 1.8k citations
Hit Papers
Peers
Shampa Das
Kayo Ikeda Japan
Michael S. Schwartz United States
Hugues Chanteux Belgium
Xingpei Hao United States
Asad Mustafa Karim South Korea
John Ayrton United Kingdom
Dana R. Anderson United States
Manuel Conde Spain
Alice H. Lin United States
Hongmei Xu China
Citations per year, relative to Shampa Das Shampa Das (= 1×)
peers
Kayo Ikeda
Countries citing papers authored by Shampa Das
Since
Specialization
Citations
This map shows the geographic impact of Shampa Das's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shampa Das with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shampa Das more than expected).
Fields of papers citing papers by Shampa Das
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Shampa Das. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shampa Das. The network helps show where Shampa Das may publish in the future.
Co-authorship network of co-authors of Shampa Das
This figure shows the co-authorship network connecting the top 25 collaborators of Shampa Das. A scholar is included among the top collaborators of Shampa Das based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shampa Das. Shampa Das is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Berg, Sanne van den, Marie Attwood, Anouk E. Muller, et al.. (2025). Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driver. Journal of Antimicrobial Chemotherapy. 80(3). 752–759.
2.
Farrington, Nicola, Anne‐Grete Märtson, Adam Johnson, et al.. (2025). Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy. 80(11). 3150–3159.
3.
Farrington, Nicola, Adam Johnson, Adam J. Stevenson, et al.. (2024). Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by Pseudomonas aeruginosa. mBio. 15(2). e0316523–e0316523.
4.
Rawson, Timothy M., Nina Zhu, Ronald Galiwango, et al.. (2024). Using digital health technologies to optimise antimicrobial use globally. The Lancet Digital Health. 6(12). e914–e925.
5.
McEntee, Laura, Adam Johnson, Nicola Farrington, et al.. (2022). Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. Journal of Antimicrobial Chemotherapy. 77(12). 3349–3357.
6.
Farrington, Nicola, Laura McEntee, Adam Johnson, et al.. (2022). Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy. 66(4). e0218121–e0218121.
7.
Farrington, Nicola, Adam Johnson, Laura McEntee, et al.. (2022). Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. Journal of Antimicrobial Chemotherapy. 77(5). 1334–1343.
8.
Gatermann, Sören, Shampa Das, L. Dubreuil, et al.. (2022). Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing. Clinical Microbiology and Infection. 28(6). 764–767.
9.
Docobo-Pérez, Fernando, Nicola Farrington, Adam Johnson, et al.. (2021). Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy. 65(7). e0029321–e0029321.
10.
Das, Shampa, Adam Johnson, Laura McEntee, et al.. (2020). Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. 64(11).
11.
Das, Shampa, Richard J. Fitzgerald, Asad Ullah, et al.. (2020). Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. Antimicrobial Agents and Chemotherapy. 65(1).
12.
Johnson, Adam, Laura McEntee, Nicola Farrington, et al.. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 64(6).
13.
Li, Jianguo, Mark Lovern, Todd Riccobene, et al.. (2020). Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy. 64(4).
14.
Wright, James G., et al.. (2020). Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. Diagnostic Microbiology and Infectious Disease. 99(4). 115292–115292.
15.
McEntee, Laura, Adam Johnson, Nicola Farrington, et al.. (2019). Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. Antimicrobial Agents and Chemotherapy. 63(8).
16.
Nicolau, David P., Leonard Siew, J. Armstrong, et al.. (2015). Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. Journal of Antimicrobial Chemotherapy. 70(10). 2862–2869.
17.
Edeki, Timi, et al.. (2015). Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers. Journal of Infection and Chemotherapy. 21(8). 551–558.
18.
Vishwanathan, Karthick, Stuart Mair, Anshul Gupta, et al.. (2014). Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential. Drug Metabolism and Disposition. 42(5). 932–942.
19.
Schwartz, Gary K., Richard D. Carvajal, Rachel Midgley, et al.. (2012). Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Investigational New Drugs. 31(2). 370–380.
20.
Boss, David S., Petronella O. Witteveen, Martijn P. Lolkema, et al.. (2010). Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Annals of Oncology. 22(2). 431–437.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kayo Ikeda Breakdown of academic impact, for papers by Michael S. Schwartz Breakdown of academic impact, for papers by Hugues Chanteux Breakdown of academic impact, for papers by Xingpei Hao Breakdown of academic impact, for papers by Asad Mustafa Karim Breakdown of academic impact, for papers by John Ayrton Breakdown of academic impact, for papers by Dana R. Anderson Breakdown of academic impact, for papers by Manuel Conde Breakdown of academic impact, for papers by Alice H. Lin Breakdown of academic impact, for papers by Hongmei Xu